
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Nov-26)
Returns (Since Inception)
Fund Size
₹9,087 Cr
Expense Ratio
1.00%
ISIN
INF204K01I50
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
01 Jan 2013
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+12.73%
+19.12% (Cat Avg.)
3 Years
+17.59%
+21.25% (Cat Avg.)
5 Years
+14.78%
+15.53% (Cat Avg.)
10 Years
+16.59%
+15.71% (Cat Avg.)
Since Inception
+17.53%
— (Cat Avg.)
| Equity | ₹9,051.24 Cr | 99.60% |
| Others | ₹36.01 Cr | 0.40% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹1,049.97 Cr | 11.55% |
| Divi's Laboratories Ltd | Equity | ₹611.99 Cr | 6.73% |
| Cipla Ltd | Equity | ₹564.67 Cr | 6.21% |
| Lupin Ltd | Equity | ₹559.86 Cr | 6.16% |
| Dr Reddy's Laboratories Ltd | Equity | ₹556.82 Cr | 6.13% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹463.62 Cr | 5.10% |
| Mankind Pharma Ltd | Equity | ₹399.74 Cr | 4.40% |
| Sai Life Sciences Ltd | Equity | ₹366.91 Cr | 4.04% |
| Ajanta Pharma Ltd | Equity | ₹320.68 Cr | 3.53% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹300.84 Cr | 3.31% |
| Ipca Laboratories Ltd | Equity | ₹263.1 Cr | 2.90% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹256.78 Cr | 2.83% |
| Gland Pharma Ltd | Equity | ₹247.84 Cr | 2.73% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹241.67 Cr | 2.66% |
| Piramal Pharma Ltd | Equity | ₹237.41 Cr | 2.61% |
| Medplus Health Services Ltd | Equity | ₹205.59 Cr | 2.26% |
| Fortis Healthcare Ltd | Equity | ₹204.04 Cr | 2.25% |
| Abbott India Ltd | Equity | ₹201.35 Cr | 2.22% |
| Dr. Lal PathLabs Ltd | Equity | ₹190.75 Cr | 2.10% |
| Thyrocare Technologies Ltd | Equity | ₹175.13 Cr | 1.93% |
| Alkem Laboratories Ltd | Equity | ₹165.51 Cr | 1.82% |
| Narayana Hrudayalaya Ltd | Equity | ₹141.73 Cr | 1.56% |
| Syngene International Ltd | Equity | ₹141.01 Cr | 1.55% |
| Aurobindo Pharma Ltd | Equity | ₹128.93 Cr | 1.42% |
| Suraksha Diagnostic Ltd | Equity | ₹123.26 Cr | 1.36% |
| Emcure Pharmaceuticals Ltd | Equity | ₹119.97 Cr | 1.32% |
| Anthem Biosciences Ltd | Equity | ₹117.69 Cr | 1.30% |
| Pfizer Ltd | Equity | ₹117.36 Cr | 1.29% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹98.9 Cr | 1.09% |
| Sanofi India Ltd | Equity | ₹96.21 Cr | 1.06% |
| Biocon Ltd | Equity | ₹88.09 Cr | 0.97% |
| Natco Pharma Ltd | Equity | ₹81.37 Cr | 0.90% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹73.55 Cr | 0.81% |
| Molbio Diagnostics Ltd | Equity | ₹48.45 Cr | 0.53% |
| Triparty Repo | Cash - Repurchase Agreement | ₹47.35 Cr | 0.52% |
| AstraZeneca Pharma India Ltd | Equity | ₹42.15 Cr | 0.46% |
| Indoco Remedies Ltd | Equity | ₹34.4 Cr | 0.38% |
| Concord Biotech Ltd | Equity | ₹13.92 Cr | 0.15% |
| Net Current Assets | Cash | ₹-11.52 Cr | 0.13% |
| Cash Margin - Ccil | Cash - Repurchase Agreement | ₹0.18 Cr | 0.00% |
Large Cap Stocks
29.61%
Mid Cap Stocks
40.77%
Small Cap Stocks
28.69%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹9,051.24 Cr | 99.60% |
Standard Deviation
This fund
14.87%
Cat. avg.
16.11%
Lower the better
Sharpe Ratio
This fund
0.82
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.63
Higher the better
ISIN INF204K01I50 | Expense Ratio 1.00% | Exit Load 1.00% | Fund Size ₹9,087 Cr | Age 13 years 10 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹7,86,131 Cr
Address
4th Floor, Tower A, Peninsula Business Park, Mumbai, 400 013
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments